• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Theragenics Corporation(R) Secures Major GPO Agreement; Company Will Supply Both TheraSeed(R) AND I-Seed to Amerinet Members

Posted on: Thursday, 28 July 2005, 09:01 CDT

Theragenics Corporation(R) (NYSE: TGX), a provider of brachytherapy and wound closure products that include TheraSeed(R), its premier palladium-103 prostate cancer treatment device and its CP Medical product line, today announced that it has been awarded a contract to offer discounted pricing on brachytherapy seeds to the members of the Amerinet group purchasing organization (GPO). Theragenics(R) will offer contract pricing on both its palladium-103 brachytherapy product, TheraSeed(R), and its iodine-125 product, I-Seed, to Amerinet's 23,000 plus members. Amerinet is based in St. Louis, Missouri. This award establishes Theragenics as one of the sources for brachytherapy seeds as part of a dual-source contract, and has a three-year term that commences September 1, 2005.

Commenting on the award, Ms. M. Christine Jacobs, Chief Executive Officer and President of Theragenics, stated, "We are pleased to have the opportunity to work with Amerinet. This organization enjoys a reputation as an innovative and highly ethical GPO. They are committed to delivering value to their membership, and we are delighted that they chose TheraSeed(R) and I-Seed as part of their value proposition."

Tom L. Emmerson, Senior Contract Manager, Diagnostic Imaging, at Amerinet commented, "Theragenics' products fit well with Amerinet's goal of ensuring its members receive the best match in both value and quality. We are pleased to be the first major GPO to begin a relationship with this leading, long-time provider of brachytherapy products."

Ms. Jacobs concluded the remarks by saying, "As a supporter of the brachytherapy marketplace, and a dedicated supplier of brachytherapy products, securing these type agreements helps achieve Theragenics' strategy of ensuring adequate channels of distribution for our seeding products. We look forward to beginning this relationship with Amerinet, and to supplying its members with the high-quality products and superior customer care that they deserve."

About Theragenics Corporation(R)

Theragenics Corporation (NYSE: TGX) is a provider of brachytherapy and wound closure products. The Georgia-based medical device company manufactures and markets its premier product, the palladium-103 TheraSeed(R) device (www.theraseed.com,) and I-Seed, an iodine-125 device, which are used in the minimally invasive treatment of localized prostate cancer. Through its subsidiary, CP Medical (www.cpmedical.com), the Company also manufactures and distributes medical products for diverse markets including wound closure and cardiac pacing, as well as the general, dental, cosmetic and veterinary surgery markets. The Company is the world's largest producer of palladium-103 and is exploring the development of new medical devices. As a result, Theragenics(R) continues to expand its legacy of delivering products that change lives for the better. For additional information, call the Company's Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.

About Amerinet

Amerinet is one of the most innovative and effective health care group purchasing organizations in the United States, partnering with members to improve their operating margins. Amerinet leads the industry in flexibility with a commitment to providing supplier choice for its members. Amerinet's national network of companies - Amerinet Central, Intermountain Health Care and Vector - has set the standard for customer service for nearly two decades. More than 1,860 hospitals and 21,000 non-acute care facilities find cost savings and value-added services through Amerinet's comprehensive contract portfolio. Members trust Amerinet to deliver proactive information and integrity.

This release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding optimism for Theragenics' sales organization and its growth, the ability of Amerinet to provide a new sales channel for Theragenics' products, new sales and marketing initiatives, Theragenics' relationship with its distributors, and anticipated positive results in general. Actual results may differ materially due to a variety of factors, including, among other things, risks and effectiveness and execution of marketing and sales programs by Theragenics and its distributors, changes in product pricing by Theragenics or other brachytherapy seed producers, changes in costs of materials used in production processes (especially as it relates to isotope production), continued acceptance of the products by the market, continued demand for palladium-103, introduction and/or availability of competitive products by others, third-party (including CMS) reimbursement, physician training, third-party distribution agreements, and other factors set forth from time to time in the Company's Securities and Exchange Commission filings.

All forward looking statements and cautionary statements included in this document are made as of the date hereby based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward looking statement or cautionary statement.

Source: Business Wire

More News in this Category